Document Type : Original Article


Department of Pharmacy Practice, Palamuru University (Smt. Sarojini Ramulamma College of Pharmacy), Sheshadrinagar, Mahabubnagar, 509001, Telangana, India


More than 75% of women have uterine fibroids (leiomyomas), which may have major morbid effects. By far, they are the main reason for a hysterectomy. Smooth muscle cells and fibroblasts make up the complicated cellular assemblage known as fibroids. They generally develop from somatic mutations, most often MED12, and are rich in the extracellular matrix. They provide chances to investigate fundamental mechanisms due to their lack of inhibition of growth and their capacity to display aspects of malignancy while remaining histologically and physiologically benign. The processes behind the genesis and evolution of leiomyomas remain a mystery. In the current research, 102 individuals were found, 12 of whom were removed for a variety of reasons, and 90 patients' data were analyzed. Age prevalence is evaluated in the topic, and risk factors, pharmaceutical therapy, surgical alternatives, and consequences are examined. According to this research, women between the ages of 31 and 40 are more likely to develop uterine fibroids, and age, obesity, and hormone imbalance are risk factors. Anti-fibrinolytic agents are a first-line therapy in the pharmacological management of menstrual bleeding. Hysterectomy is the recommended surgical procedure for the treatment of uterine fibroids. Our research found that excessive or prolonged bleeding and unfavourable pregnancy outcomes were the main symptoms. This research shows that uterine fibroids have a major influence on one's quality of life.

Graphical Abstract

A study on uterine fibroids effective treatment and associated risks factors in the tertiary care teaching hospital


Main Subjects

Selected author of this article by journal

Dr.  Satish Kumar
Palamuru University

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit:


Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.


Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Stewart EA, Nowak RA (2022) Uterine fibroids: hiding in plain sight. Physiology 37 (1): 16-27. doi:
  2. Somigliana E, Vercellini P, Daguati R, Pasin R, De Giorgi O, Crosignani P (2007) Fibroids and female reproduction: a critical analysis of the evidence. Human Reproduction Update 13 (5): 465-476. doi:
  3. Pritts EA, Parker WH, Olive DL (2009) Fibroids and infertility: an updated systematic review of the evidence. Fertility and sterility 91 (4): 1215-1223. doi:
  4. Munro MG, Critchley HO, Fraser IS, Committee FMD, Haththotuwa R, Kriplani A, Bahamondes L, Füchtner C, Tonye R, Archer D (2018) The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. International Journal of Gynecology & Obstetrics 143 (3): 393-408. doi:
  5. Sriprasert I, Pakrashi T, Kimble T, Archer DF (2017) Heavy menstrual bleeding diagnosis and medical management. Contraception and reproductive medicine 2): 1-8. doi:
  6. Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, Al-Hendy A (2022) Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocrine reviews 43 (4): 678-719. doi:
  7. Szydłowska I, Nawrocka-Rutkowska J, Brodowska A, Marciniak A, Starczewski A, Szczuko M (2022) Dietary natural compounds and vitamins as potential cofactors in uterine fibroids growth and development. Nutrients 14 (4): 734. doi:
  8. Stewart EA (2015) Uterine fibroids. New England Journal of Medicine 372 (17): 1646-1655. doi:
  9. Amoah A, Joseph N, Reap S, Quinn S (2022) Appraisal of national and international uterine fibroid management guidelines: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology 129 (3): 356-364. doi:
  10. Hartmann K, Fonnesbeck C, Surawicz T, Krishnaswami S, Andrews J, Wilson J, Velez-Edwards D, Kugley S, Sathe N (2017) Management of uterine fibroids. Comparative effectiveness review no. 195. Rockville, MD: Agency for Healthcare Research and Quality. doi:
  11. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A (2003) Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertility and sterility 79 (5): 1194-1198. doi:
  12. Kai J, Dutton B, Vinogradova Y, Hilken N, Gupta J, Daniels J (2022) Medical treatment for heavy menstrual bleeding in primary care: 10-year data from the ECLIPSE trial. British Journal of General Practice 72 (725): e857-e864. doi:
  13. Marret H, Fritel X, Ouldamer L, Bendifallah S, Brun J-L, De Jesus I, Derrien J, Giraudet G, Kahn V, Koskas M (2012) Therapeutic management of uterine fibroid tumors: updated French guidelines. European Journal of Obstetrics & Gynecology and Reproductive Biology 165 (2): 156-164. doi:
  14. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser B, Barlow D, Palacios S, Donnez O, Bestel E (2014) PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate Fertil Steril 101): 1565-1573. doi:
  15. Esteve JLC, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS (2012) Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. European Journal of Obstetrics & Gynecology and Reproductive Biology 161 (2): 202-208. doi:
  16. Daniels J, Middleton LJ, Cheed V, McKinnon W, Rana D, Sirkeci F, Manyonda I, Belli A-M, Lumsden MA, Moss J (2022) Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT. Health Technology Assessment (Winchester, England) 26 (22): 1-74. doi:
  17. Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E, Reekers JA, Ankum WM (2007) Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Human reproduction 22 (7): 1996-2005. doi:
  18. Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynnen K, Macdanold N, Inbar Y, Itzchak Y, Rabinovici J (2004) MRI guidance of focused ultrasound therapy of uterine fibroids: early results. American Journal of Roentgenology 183 (6): 1713-1719. doi:
  19. Faerstein E, Szklo M, Rosenshein N (2001) Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. American journal of epidemiology 153 (1): 1-10. doi:
  20. Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Steege JF, Hill MC, Schectman JM, Hartmann KE (2003) Self-reported heavy bleeding associated with uterine leiomyomata. Obstetrics & Gynecology 101 (3): 431-437. doi:
  21. Ciebiera M, Włodarczyk M, Słabuszewska-Jóźwiak A, Nowicka G, Jakiel G (2016) Influence of vitamin D and transforming growth factor β3 serum concentrations, obesity, and family history on the risk for uterine fibroids. Fertility and Sterility 106 (7): 1787-1792. doi:
  22. Moroni R, Vieira C, Ferriani R, CandidodosReis F, Brito L (2014) Pharmacological treatment of uterine fibroids. Annals of medical and health sciences research 4 (3): 185-192. doi:
  23. Mas A, Tarazona M, Dasí Carrasco J, Estaca G, Cristóbal I, Monleón J (2017) Updated approaches for management of uterine fibroids. International journal of women's health 4 (3): 607-617. doi:
  24. Investigators R (2007) Uterine-artery embolization versus surgery for symptomatic uterine fibroids. New England Journal of Medicine 356 (4): 360-370. doi: